![Llinos Honeybun](https://profiles-cardiff.imgix.net/attachments/6654?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Llinos Honeybun
- Welsh speaking
Teams and roles for Llinos Honeybun
Research Associate
School of Biosciences
Overview
I'm a research associate at the Medicines Discovery Institute (MDI) working on lysosomal disorders.
My PhD project with Prof Emyr Lloyd-Evans investigated novel treatments for a rare childhood neurodegenerative disorder called CLN3 disease (also referred to as Batten disease). This disorder affects children from the age of 4+ and symptoms include loss of vision, seizures and later, motor and cognitive decline. During this project, I developed and undertook a high- throughput drug screen to uncover compounds that could be repurposed for CLN3 disease.
Publication
2023
- Best, H. et al. 2023. The Batten disease associated protein CLN3 is required for the efflux of lysosomal K. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.47-47. (10.1016/j.ymgme.2022.107030)
- Honeybun, L. , Waller-Evans, H. and Lloyd-Evans, E. 2023. Unbiased phenotypic drug screen for CLN3 disease. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.167-167. (10.1016/j.ymgme.2022.107150)
- Lloyd-Evans, E. et al. 2023. Glycosphingolipid reduction with miglustat as a therapeutic strategy for CLN3 and other neuronal ceroid lipofuscinoses.. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.84. (10.1016/j.ymgme.2022.107212)
- Waller-Evans, H. et al. 2023. Measuring ion flux via lysosomal channels: Primary and secondary assays for drug discovery across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.133-134. (10.1016/j.ymgme.2022.107353)
Conferences
- Best, H. et al. 2023. The Batten disease associated protein CLN3 is required for the efflux of lysosomal K. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.47-47. (10.1016/j.ymgme.2022.107030)
- Honeybun, L. , Waller-Evans, H. and Lloyd-Evans, E. 2023. Unbiased phenotypic drug screen for CLN3 disease. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.167-167. (10.1016/j.ymgme.2022.107150)
- Lloyd-Evans, E. et al. 2023. Glycosphingolipid reduction with miglustat as a therapeutic strategy for CLN3 and other neuronal ceroid lipofuscinoses.. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.84. (10.1016/j.ymgme.2022.107212)
- Waller-Evans, H. et al. 2023. Measuring ion flux via lysosomal channels: Primary and secondary assays for drug discovery across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.133-134. (10.1016/j.ymgme.2022.107353)
Research
Funding successes:
Drug Discovery Innovation Bid and a Javier Uceda ECR Secondment Fund for 'High-Throughput Drug Screening for Childhood Neurodegenerative Disorders'.
Cardiff UKRI MRC IAA fund for a project titled 'Validating phenotypic drug hits in human-derived models of CLN3 disease: Toward translational impact'.
Biography
2025-Current.
Research Associate at the MDI. I continue to work within lysosomal cell biology, investigating novel drug therapies for lysosomal storage disorders.
2021-2025
PhD Student with Prof. Emyr Lloyd-Evans. I characterised CLN3 disease cells phenotypically through microscopy and developed a drug-screening assay to identify compounds suitable for repurposing. I then completed the drug screening at a specialist high throughput drug screening facility in Vancouver, Canada.
2019-2021
Genetic Technologist at the All Wales Medial Genomics Service at NHS Wales. I was part of the clinical team analysing patient genetic data to provide targeted cancer treatment for patients with specific genetic mutations.
2017-2019
Development Scientist at BBI Solutions. Here, I developed several lateral flow device technologies for several markers from proof of concept to validation.
2016-2017
MSc Forensic Science at Strathclyde University. My research project investigated post-mortem drug re-distribution through non-destructive X-Ray CT scanning.
2012-2016
BSc Pharmacology at Bath University with a placement year at Cardiff University investigating the role of endocytosis in Alzheimer's disease. My final year project investigated alternative therapies for epilepsy using electrophysiology techniques using mouse brain slices.
Contact Details
Research themes
Specialisms
- Animal cell and molecular biology
- Fluorescence microscopy
- Translational Drug Discovery
- Drug Screening